A study of 468 healthy newborns shows that infants given the
probiotic Lactobacillus reuteri Protectis cried less than half as
long as infants given a placebo. The infants given Lactobacillus
reuteri Protectis also had significantly fewer daily regurgitations
and were less constipated compared to infants in the placebo group. As a
result, the use of Lactobacillus reuteri Protectis proved to be
cost saving for both parents and the community.
Dr Flavia Indrio (Photo: Business Wire)
"This is the first study proving prophylactic use of a specific strain
(L. reuteri Protectis) in a condition like functional
gastrointestinal disorders (colic, regurgitation and constipation).
Moreover this is also the first evaluation of the cost/benefit for a
probiotic therapy in infants and it shows that L. reuteri
Protectis is valuable for the family and for the society," says Doctor
Flavia Indrio, MD, Department of Paediatrics, University of Bari, Italy.
Less crying, less constipation, less regurgitation…
Intervention started the first days of life. After one month's use of Lactobacillus
reuteri Protectis drops the infants cried less than half as long per
day as the infants given placebo, 45 minutes compared to 96 minutes. The
significant difference between the groups persisted to the end of the
three months' intervention.
The infants in the Lactobacillus reuteri Protectis group aso had
a better gut motility, leading to significantly more daily evacuations
and less regurgitation compared to infants in the placebo group.
…means less costs for family and community
Not only could colic, regurgitation and constipation cause the baby
pain. These conditions often lead to numerous visits to the
paediatrician and also hospitalisation and use of drugs, as well as
anxiety and loss of working days for the parents. Only by calculating
the direct costs, the investigators concluded that use of Lactobacillus
reuteri Protectis saved each family 88 euro. In addition to this the
community saved 104 euro per child.
"This study is ground breaking as it shows that BioGaia's product should
be given to all babies from birth. Not only does it reduce suffering in
babies and parents, but it also saves the families and the society
costs. This study will be immensely important for the further
development of BioGaia's baby segment," says Peter Rothschild, President
The study was published in the highly regarded medical journal JAMA
on 13 January 2014. More information
on colic, constipation, regurgitation, study
details and an interview
with Dr Indrio is found through attached links.
BioGaia is a healthcare company that develops, markets and sells
probiotic products with documented health benefits. The products are
primarily based on the lactic acid bacterium Lactobacillus reuteri
which has probiotic, health-enhancing effects. The class B share of the
Parent Company BioGaia AB (STO:BIOG-B) is quoted on the Mid Cap list of
the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140113006786/en/
[ Back To NFVZone's Homepage ]